Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma.

By Georgina V. Long, D. Stroyakovskiy, H. Gogas, E. Levchenko, F. de Braud, J. Larkin, C. Garbe, T. Jouary, A. Hauschild, J. Grob and 25 more. New England Journal of Medicine, 2014

1,768 citations recorded by the source corpus.

Subfields: Cancer Research, Molecular Biology, Oncology

View Paper: https://www.semanticscholar.org/paper/77576e6e5bfdfab5ea803c412432bbe34b34b560

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

1. K. Flaherty
2. Georgina V. Long

Citations in the corpus

• Melanoma Staging: Evidence-Based Changes in the American Joint Committee on Cancer Eighth Edition Cancer Staging Manual (2017, methodology): “as well as stratification and analysis, are often based on the presence/absence of CNS disease.(6-20,73,74) Therefore, this additional level of granularity in the M category “maps” bet-”
• Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma (2015, neutral): “(% [95% CI])† 44 (61 [49–72]) 4 (11 [3–25]) 12 (52 [31–73]) 1 (10 [0–45])”
• Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer. (2018, neutral): “Total 93 (93) 42 (42) 15 (94) 8 (50) Fatigue 38 (38) 5 (5) 7 (44) 1 (6) Pyrexia 37 (37) 4 (4) 5 (31) 0 Nausea 35 (35) 1 (1) 5 (31) 0 Chills 28 (28) 1 (1) 4 (25) 0 Vomiting 24 (24) 1 (1) 4 (25) 0 Headache 22 (22) 2 (2) 3 (19) 0 Cough 21 (21) 0 2 (13) 0 Diarrhea 20 (20) 1 (1) 4 (25) 1 (6) Anemia 18 (1”